126 related articles for article (PubMed ID: 36517653)
1. Hip and vertebral fracture risk after initiating antidiabetic drugs in Japanese elderly: a nationwide study.
Tamaki J; Ogawa S; Fujimori K; Ishii S; Nakatoh S; Okimoto N; Kamiya K; Iki M
J Bone Miner Metab; 2023 Jan; 41(1):29-40. PubMed ID: 36517653
[TBL] [Abstract][Full Text] [Related]
2. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
Driessen JH; van den Bergh JP; van Onzenoort HA; Henry RM; Leufkens HG; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):421-428. PubMed ID: 27943565
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
Komamine M; Kajiyama K; Ishiguro C; Uyama Y
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1166-1174. PubMed ID: 31338935
[TBL] [Abstract][Full Text] [Related]
4. Average daily glucocorticoid dose, number of prescription days, and cumulative dose in the initial 90 days of glucocorticoid therapy are associated with subsequent hip and clinical vertebral fracture risk: a retrospective cohort study using a nationwide health insurance claims database in Japan.
Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Imano H; Ogawa S
Osteoporos Int; 2024 May; 35(5):805-818. PubMed ID: 38267664
[TBL] [Abstract][Full Text] [Related]
5. Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
Bone; 2022 Jul; 160():116396. PubMed ID: 35351673
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
[TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database.
Takeuchi Y; Kumamaru H; Hagiwara Y; Matsui H; Yasunaga H; Miyata H; Matsuyama Y
Diabetes Obes Metab; 2021 Jun; 23(6):1379-1388. PubMed ID: 33606891
[TBL] [Abstract][Full Text] [Related]
9. Association between prior non-spine non-hip fractures or prevalent radiographic vertebral deformities known to be at least 10 years old and incident hip fracture.
Schousboe JT; Fink HA; Lui LY; Taylor BC; Ensrud KE
J Bone Miner Res; 2006 Oct; 21(10):1557-64. PubMed ID: 16995810
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
11. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives.
Gokhale M; Buse JB; Jonsson Funk M; Lund J; Pate V; Simpson RJ; Stürmer T
Diabetes Obes Metab; 2017 Jul; 19(7):970-978. PubMed ID: 28195389
[TBL] [Abstract][Full Text] [Related]
12. Effect of benign prostatic hyperplasia on the development of spine, hip, and wrist fractures.
Yang SC; Chiu YC; Liu PH; Hsieh TJ; Kao YH; Tu YK
Osteoporos Int; 2019 May; 30(5):1043-1049. PubMed ID: 30706096
[TBL] [Abstract][Full Text] [Related]
13. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
14. Association between self-reported prior wrist fractures and risk of subsequent hip and radiographic vertebral fractures in older women: a prospective study.
Schousboe JT; Fink HA; Taylor BC; Stone KL; Hillier TA; Nevitt MC; Ensrud KE
J Bone Miner Res; 2005 Jan; 20(1):100-6. PubMed ID: 15619675
[TBL] [Abstract][Full Text] [Related]
15. Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population.
Ustulin M; Park SY; Choi H; Chon S; Woo JT; Rhee SY
J Korean Med Sci; 2019 Sep; 34(35):e224. PubMed ID: 31496139
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.
Hou WH; Chang KC; Li CY; Ou HT
Br J Clin Pharmacol; 2018 Sep; 84(9):2029-2039. PubMed ID: 29766544
[TBL] [Abstract][Full Text] [Related]
17. Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan.
Bouchi R; Sugiyama T; Goto A; Imai K; Ihana-Sugiyama N; Ohsugi M; Yamauchi T; Kadowaki T; Ueki K
J Diabetes Investig; 2022 Feb; 13(2):280-291. PubMed ID: 34309213
[TBL] [Abstract][Full Text] [Related]
18. Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes.
Douros A; Abrahami D; Yin H; Yu OHY; Renoux C; Hudson M; Azoulay L
Epidemiology; 2018 Nov; 29(6):904-912. PubMed ID: 30028343
[TBL] [Abstract][Full Text] [Related]
19. Impact of sodium-glucose cotransporter-2 inhibitors on the risk of hip fracture in older patients in Japan using a nationwide administrative claims database: A matched case-control study.
Saito T; Nojiri S; Kasai T; Hiratsuka Y; Ishijima M; Daida H
Geriatr Gerontol Int; 2023 Jun; 23(6):418-425. PubMed ID: 37139826
[TBL] [Abstract][Full Text] [Related]
20. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs.
Yabe D; Kuwata H; Kaneko M; Ito C; Nishikino R; Murorani K; Kurose T; Seino Y
Diabetes Obes Metab; 2015 Apr; 17(4):430-4. PubMed ID: 25146418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]